The applications of Senesco's SNS10T in cancer are discussed much more than its applications in the field of agriculture. Due to the possible benefits like increasing crop yield, the agricultural applications also hold tremendous potential. The company already has licensing arrangements with other companies, and there is small inflow related to this. As mentioned in the recently filed 10Q for the period ending Sep 30, the company received a revenue of $100,000 which pertains to a milestone payment in connection with an agricultural license agreement. The agricultural applications have the potential to generate regular inflow for the company sooner compared to the cancer therapy applications. The encouraging results in pre-clinical and the clinical trials for cancer treatment have taken away the focus from the agricultural applications. Further, the recent news about the company is also mainly related to the upcoming results of the trials on multiple myeloma. The potential of agricultural applications is underrated. This is especially true if one considers the numerous partnerships which the company has, and the patents it owns. Senesco has agreements with companies like Bayer Crop Science and Monsanto. In November 2006, it had entered into a collaboration with Bayer Crop Science to use the technology on Brassica oilseeds to improve the yield of canola. Its agreement with Monsanto in 2007 enabled the use of Senesco's yield and stress technology on corn and soybeans. Other companies with which it has agreements include Cal/West Seeds, ArborGen and Rahan Meristem. The original discovery of eIF5A was actually in plants, and the human applications were tried because the genetic sequence of eIF5A (Factor 5A) is similar to that of a plant. In any case, the immediate trigger will be the upcoming update in early December on the clinical trials related to multiple myeloma (cohort 3). Positive news will help in building momentum for the stock.
